MErCuRIC1: A phase 1a study of MEK1/2 inhibitor PD-0325901 with cMET inhibitor crizotinib in patients with advanced solid tumours
暂无分享，去创建一个
M. Salto‐Tellez | F. Nicolantonio | A. Bardelli | P. Laurent-Puig | V. Popovici | M. Lawler | S. Love | C. Rolfo | M. Peeters | C. Roberts | J. Taieb | M. Middleton | T. Maughan | S. Schaeybroeck | T. André | M. Grayson | J. Houlden | E. Élez | R. Wilson | J. Tabernero